Jan. 29, 2008 - BioMarck Pharmaceuticals, a biopharmaceutical research and development company focused on new therapies for the treatment of respiratory diseases, announced that it has obtained agreement from the U.S. Food and Drug Administration (FDA) for its proposed plans for a Phase 2 trial of the novel respiratory drug, BIO-11006 Inhalation Solution.Phase 1 studies of BIO-11006, an inhaled drug designed to combat the oversecretion of mucus and inflammation in diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, were conducted on healthy volunteers and have demonstrated that the treatment is safe and well tolerated... [FLASH] BioMarck's Press Release -
